Alameda, CA-based Penumbra, Inc. PEN has secured the CE Mark in Europe for its newest computer-assisted vacuum thrombectomy (CAVT) technologies, Lightning Flash 2.0 and Lightning Bolt 7. Lightning Flash 2.0 is the most advanced mechanical thrombectomy system available to address venous and pulmonary thrombus while the Lightning Bolt 7 stands out as the most powerful arterial thrombectomy system in the market.

The latest innovations further enhance the company’s neuro and vascular portfolios.

Likely Trend of PEN Stock Following the Announcement

Following the news, shares of PEN inched up 0.4% to $187.65 at yesterday’s close. With thrombectomy procedures gaining fast popularity globally, Penumbra has been witnessing market share gains, banking on strong customer uptake of its Lightning Bolt and Flash lines.

The latest development is likely to boost European physicians’ trust in considering CAVT as a valuable first-line option to manage conditions such as pulmonary embolism (PE), venous thrombosis and other severe cases. Henceforth, we expect the market sentiment toward the stock to remain positive, driven by this development.

More on Penumbra’s Latest CAVT Technologies

Lightning Flash 2.0 features Penumbra’s Lightning Intelligent Aspiration technology with the latest dual clot detection algorithms, using both pressure and flow-based processes to detect blood clots and blood flow. The catheter is made with MaxID hypotube technology, allowing an inner diameter similar to large-bore catheters while maintaining a lower profile and a soft, atraumatic tip design.

The design facilitates the removal of blood clots with speed, safety and simplicity, allowing physicians to navigate the body’s complex anatomy and deliver high-power aspiration for clot removal with minimal blood loss.

Image Source: Zacks Investment Research

Lightning Bolt 7 uses a new method for removing blood clots called modulated aspiration, which pairs the Lightning Intelligent Aspiration technology with an advanced microprocessor algorithm. When combined, the system is designed to rapidly remove large, fibrous blood clots in the arteries with minimal blood loss, addressing conditions such as acute limb ischemia , hibernating thrombus and visceral occlusions.

Lightning Bolt 7 is engineered to detect the difference between blood clots and blood flow. Additionally, it is designed to break the friction between the catheter and clot by having the computer algorithms rapidly modulate aspiration to quickly fatigue the thrombus and remove the clot from the arteries.